Search

Now showing items 1-8 of 8

Temporary use authorizations : the economic and clinical future of drugs used in the french compassionate program

Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Sinègre, Martine; Degrassat-Théas, Albane (2011) Article accepté pour publication ou publié

Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience

Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Sinègre, Martine; Le Pen, Claude (2015) Article accepté pour publication ou publié

Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis

Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014) Article accepté pour publication ou publié

Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?

Degrassat-Théas, Albane; Paubel, Pascal; Parent de Curzon, Olivier; Le Pen, Claude; Sinègre, Martine (2013) Article accepté pour publication ou publié

Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures

Degrassat-Théas, Albane; Bensadon, M.; Rieu, C.; Angalakuditi, M.; Le Pen, Claude; Paubel, Pascal (2012) Article accepté pour publication ou publié

Is Orphan Designation a Driver of Orphan Drug Pricing?

Degrassat-Théas, Albane; Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Poisson, N.; Sinègre, Martine (2012) Article accepté pour publication ou publié

To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis

Fusier, Isabelle; Cordonnier, Anne-Laure; Paubel, Pascal; Bocquet, François; Le Pen, Claude (2013) Article accepté pour publication ou publié

A Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Markets